2017
Nine‐month results of the BIOHELIX‐I clinical trial study: Evaluation of the PRO‐Kinetic Energy cobalt chromium bare‐metal stent system
Michael TT, Richardt G, Lansky A, Carney RJ, Khan MA, Shehadeh A, Zeymer U, Gupta S. Nine‐month results of the BIOHELIX‐I clinical trial study: Evaluation of the PRO‐Kinetic Energy cobalt chromium bare‐metal stent system. Catheterization And Cardiovascular Interventions 2017, 92: 1030-1039. PMID: 29271575, DOI: 10.1002/ccd.27434.Peer-Reviewed Original ResearchConceptsTarget vessel revascularizationCoronary artery diseaseIschemia-driven target vessel revascularizationBare metal stentsTarget vessel failureTVF ratePrimary endpointStent systemSymptomatic coronary artery diseaseTarget lesion revascularization rateSingle-arm clinical trialNine‐month resultsDual antiplatelet therapyLesion revascularization rateMean patient agePercutaneous coronary interventionSubset of patientsClinical trial studyPrespecified performance goalArm clinical trialCoronary stent systemDrug-eluting stentsMean lesion lengthMajority of implantsEligible patients
2015
The Variation in Recovery
Spatz ES, Curry LA, Masoudi FA, Zhou S, Strait KM, Gross CP, Curtis JP, Lansky AJ, Soares Barreto-Filho JA, Lampropulos JF, Bueno H, Chaudhry SI, D'Onofrio G, Safdar B, Dreyer RP, Murugiah K, Spertus JA, Krumholz HM. The Variation in Recovery. Circulation 2015, 132: 1710-1718. PMID: 26350057, PMCID: PMC4858327, DOI: 10.1161/circulationaha.115.016502.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge of OnsetAlgorithmsAortic DissectionClassificationCoronary DiseaseDiagnostic Techniques, CardiovascularFemaleHumansMaleMedical RecordsMiddle AgedMyocardial InfarctionMyocardiumOxygen ConsumptionPhenotypePlaque, AtheroscleroticProspective StudiesReproducibility of ResultsRisk FactorsSex FactorsTreatment OutcomeYoung AdultConceptsAcute myocardial infarctionCoronary artery diseaseArtery diseaseClinical phenotypeNonobstructive coronary artery diseaseYoung AMI Patients (VIRGO) studyObstructive coronary artery diseaseYoung womenType 2 acute myocardial infarctionBiological disease mechanismsSubset of patientsThird universal definitionUnique clinical phenotypeCulprit lesionClinical characteristicsMyocardial infarctionTherapeutic efficacyUniversal definitionStudy participantsPatientsSupply-demand mismatchYoung adultsDisease mechanismsPatient studiesCurrent classification schemes
2006
Usefulness of Routine Unfractionated Heparin Infusion Following Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction in Patients Not Receiving Glycoprotein IIb/IIIa Inhibitors
Harjai KJ, Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Na Y, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Rutherford BD, Lansky AJ, Mehran R. Usefulness of Routine Unfractionated Heparin Infusion Following Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction in Patients Not Receiving Glycoprotein IIb/IIIa Inhibitors. The American Journal Of Cardiology 2006, 99: 202-207. PMID: 17223419, DOI: 10.1016/j.amjcard.2006.07.084.Peer-Reviewed Original ResearchConceptsPercutaneous transluminal coronary angioplastyPrimary percutaneous coronary interventionGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsAcute myocardial infarctionPercutaneous coronary interventionHeparin usePostprocedural heparinCoronary interventionMyocardial infarctionHospital major adverse cardiac eventsPrimary PCIMajor adverse cardiac eventsUnfractionated heparin infusionAdverse cardiac eventsOutcomes of patientsSubset of patientsTransluminal coronary angioplastyLate MACEPostprocedure courseHeparin infusionCardiac eventsCoronary angioplastyCoronary stentingSevere bleeding